SCHEMBL719752

SCHEMBL719752

O=C(N1CCc2cc3ccc(=O)[nH]c3cc2CC1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.48
ESR2 Q92731 4/20 0.48
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR1 P21554 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MGLL Q99685 2/20 0.38
AR P10275 1/20 0.37
HRH4 Q9H3N8 4/20 0.37
KIF11 P52732 1/20 0.37
ABCB1 P08183 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL722169 0.77 AR (0.38) ARKIF11MAPK1
SCHEMBL718874 0.77 ESR1 (0.43) ESR1ESR2KDM4EALDH1A1POLB
SCHEMBL13849655 0.73 CA12 (0.48) KDM4EALDH1A1KMT2AARKIF11
SCHEMBL13849654 0.73 GRIN2D (0.53) ARKIF11MAPK1
SCHEMBL13849659 0.72 CA12 (0.47) KDM4EALDH1A1KMT2AARKIF11
SCHEMBL722817 0.71 ESR1 (0.51) ESR1ESR2SMN1; SMN2KMT2ADRD2
SCHEMBL719456 0.70 ESR1 (0.56) ESR1ESR2
SCHEMBL718661 0.70 CA12 (0.46) ARKIF11DRD2DRD3MAPK1
SCHEMBL506139 0.70 ESR1 (0.59) ESR1ESR2ALDH1A1SMN1; SMN2NPC1
SCHEMBL373697 0.70 ESR2 (0.83) ESR1ESR2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA10 ESR1 1178/4885ESR2 825/4885KDM4E 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.